Why Did Suboxone ANDA Applicant Forfeit 180-Day Exclusivity? US FDA's Answer Sets New Policy
Executive Summary
Agency reinterprets definition of "first applicant" and applies "failure to market" forfeiture provision of MMA; court halts sales of Dr. Reddy's generic.
You may also be interested in...
Indivior Withdraws 2018 Guidance Due To Competitive Pressures On Suboxone, Sublocade
Suboxone market share has declined with the at-risk launch of Dr. Reddy’s generic competitor, while Indivior awaits a court decision on a requested temporary restraining order against the launch.
Dr. Reddy's Launches First Generic Suboxone Film; Indivior May Seek Injunction
Launch comes immediately after FDA approval of Dr. Reddy's and Mylan ANDAs while Indivior appeals district court ruling of non-infringement; Mylan settlement may delay its entry.
Indivior To Appeal US Suboxone Setback, Flags Follow-On Drug RBP-6000
Shares in Indivior slid nearly 40% on news of a US court ruling which raises chances its key opioid addiction treatment may face generic competition sooner than expected.